Innovating Works

QBIO

Desconocido
PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 QBIOLOGICALS NV participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado
HOOKVAC: Developing and Testing a novel low cost effective HOOKworm VACcine to Control Human Hookworm Infec... QBIOLOGICALS NV participó en un FP7: Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm...
Financiado
STREPSYNTH: Rewiring the Streptomyces cell factory for cost effective production of biomolecules QBIOLOGICALS NV participó en un FP7: STREPSYNTH aims to set-up a Streptomyces-based new industrial production platform (SNIP) for high value added biomolecules. Streptomyces liv...
Financiado
FLUNIVAC: InFLUenza virus UNIVersal VACcine development program QBIOLOGICALS NV participó en un FP7: "Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses co...
Financiado
TA101-GOCLIN: Clinical development of TA 101 for the treatment of rheumatoid arthritis QBIOLOGICALS NV participó en un FP7: The aim of TA101GOCLIN Project is to take TA101 into the clinical stage of development for rheumatoid arthritis and prepare the product for...
Financiado
CDVAX: Oral Vaccination against Clostridium difficile Infection QBIOLOGICALS NV participó en un FP7: Clostridium difficile infection (CDI) is a major threat to public health in the industrialised world, particularly in Europe. In many EU cou...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.